What exactly is happening inside a dog's joints with IMPA?

Immune-mediated polyarthritis is not a single disease but a syndrome in which circulating immune complexes—clusters of antibody bound to antigen—settle into the synovial fluid of joints and trigger an inflammatory cascade rather than fighting an actual pathogen there. The Merck Veterinary Manual describes this as a type III hypersensitivity reaction, where complement activation draws neutrophils into joints that have no infection to clear, and those neutrophils release enzymes that damage cartilage over time (Merck Veterinary Manual, 2024).

Most dogs diagnosed with IMPA are classified as having the erosive or non-erosive form based on whether joint cartilage and underlying bone show permanent damage on imaging. The non-erosive form is far more common, accounting for the large majority of canine cases according to veterinary rheumatology reviews, and it tends to respond better to immunosuppressive therapy because the joint architecture itself hasn't yet been destroyed (Cornell Riney Canine Health Center, n.d.).

What do owners usually notice first?

Because IMPA hits multiple joints simultaneously rather than one, the earliest sign is often a shifting-leg lameness—a dog that favors the left front leg one day and the right hind the next, which can make owners assume they're dealing with separate injuries. Affected dogs frequently run a low-grade fever in the 103 to 105°F range (normal is roughly 101 to 102.5°F), become reluctant to rise, and walk with a stiff, short-strided gait described by veterinary internists as a 'walking on eggshells' presentation (ACVIM, n.d.).

Lethargy and reduced appetite commonly accompany the joint signs, and some dogs develop swollen, warm joints that are painful to flex—most noticeably at the carpi (wrists) and tarsi (hocks), which sit farthest from the body and seem to accumulate immune complexes more readily. Because these systemic signs mimic a broader infection, many dogs are initially treated for something else before joint-specific testing points to IMPA (Merck Veterinary Manual, 2024).

What triggers this immune reaction in the first place?

In an estimated 50% or more of canine cases, no inciting cause is ever found, and veterinarians classify these as primary or idiopathic IMPA (Merck Veterinary Manual, 2024). When a cause is identified, it's termed secondary IMPA, and the trigger list is broad: chronic bacterial infections such as dental disease or discospondylitis, tick-borne illnesses including Anaplasma and Ehrlichia species, chronic skin or gastrointestinal inflammation, certain cancers, and even reactions to some medications and recent vaccinations have all been documented as antigen sources that seed immune complex formation.

Breed-associated forms also exist; Akitas, and to a lesser extent Shar-Peis, have a recognized predisposition to a familial polyarthritis syndrome that can appear in young adulthood, suggesting a genetic component layered on top of the general immune-complex mechanism (Cornell Riney Canine Health Center, n.d.). Distinguishing primary from secondary matters clinically, because secondary IMPA generally will not resolve with immunosuppressive drugs alone if the underlying infection or tumor driving it isn't also addressed.

How do veterinarians actually confirm a diagnosis?

The definitive test is arthrocentesis—inserting a needle into affected joints to withdraw synovial fluid for cytologic analysis. In IMPA, that fluid typically shows a markedly increased white blood cell count dominated by non-degenerate neutrophils, without the bacteria that would indicate septic arthritis, a distinction that is central to ruling out infection before starting immune-suppressing treatment (Merck Veterinary Manual, 2024). Vets commonly sample four or more joints, since findings can vary between joints and a single normal tap doesn't rule out the disease elsewhere.

Beyond joint fluid, a full secondary-cause workup is standard: bloodwork including a complete blood count and chemistry panel, urinalysis, tick-borne disease titers or PCR testing, chest and abdominal imaging to screen for occult cancer or infection, and sometimes ANA (antinuclear antibody) testing when systemic lupus erythematosus is suspected as an underlying driver. This layered testing approach reflects the reality that treating primary IMPA is straightforward compared to hunting down a hidden secondary cause (ACVIM, n.d.).

What does treatment actually involve, and how long does it take?

For primary IMPA, the mainstay is immunosuppressive medication, most often oral prednisone or prednisolone at doses that suppress the aberrant immune response, sometimes combined with a second agent such as azathioprine, mycophenolate mofetil, or leflunomide for dogs that don't respond to steroids alone or that need lower long-term steroid doses to limit side effects (Merck Veterinary Manual, 2024). Many dogs show visible improvement in lameness and appetite within one to two weeks of starting therapy, but full immunosuppressive tapering protocols commonly extend four to six months or longer.

Secondary IMPA requires treating the root cause in parallel—appropriate antibiotics for a tick-borne infection or dental abscess, tumor removal, or resolution of a chronic skin condition—because immunosuppressive drugs alone can allow an underlying infection to worsen. Veterinarians typically recheck joint fluid or clinical signs at intervals during tapering rather than stopping medication abruptly, since relapse is a recognized risk if steroids are withdrawn too quickly (Cornell Riney Canine Health Center, n.d.).

How do I take care of my dog day to day during treatment?

While on immunosuppressive doses of steroids, dogs often develop increased thirst, urination, and appetite, so owners should expect more frequent bathroom breaks and may need to adjust food portions to avoid excess weight gain, which puts additional strain on already inflamed joints. Keeping a dog on soft, supportive bedding, limiting stairs and jumping, and using ramps for cars or furniture can meaningfully reduce joint stress during flare periods.

Because long-term immunosuppression raises infection risk, owners are generally advised to avoid unnecessary vaccinations during active treatment (following veterinary guidance on timing) and to watch closely for signs of secondary infection like new coughing, diarrhea, or urinary accidents, which can be harder to detect once steroids mask typical fever responses. Routine bloodwork monitoring, often every four to eight weeks initially, helps catch drug-related liver or bone marrow changes before they become serious (AAHA, n.d.).

What's the long-term outlook for a dog with this diagnosis?

Dogs with primary, non-erosive IMPA generally carry a favorable prognosis, with many achieving long-term remission or requiring only low-dose maintenance medication once the initial flare is controlled. Relapse is possible, though, and some dogs need intermittent or lifelong low-dose immunosuppressive therapy to stay comfortable, particularly if an underlying trigger is never identified (Merck Veterinary Manual, 2024).

The erosive form, which is rarer and includes conditions historically labeled as canine rheumatoid arthritis, carries a more guarded long-term outlook because cartilage and bone damage already present at diagnosis doesn't reverse with medication, meaning management shifts toward pain control and slowing further joint destruction rather than achieving a cure (Cornell Riney Canine Health Center, n.d.).